Buscar
01/12/2023
Melanoma-specific survival in worse in the elderly: a multicentric cohort study.
Segura S, Podlipnik S, Boada A, Martí RM, Sabat M, Yélamos O, Zarzoso-Muñoz I, Azón-Masoliver A, López-Castillo D, Solà J, Baliu-Piqué C, Galvany-Rossell L, Pasquali P, Just-Sarobé M, Duran X, Carrera C, Richarz NA, Pujol RM, Malvehy J, Puig S. Melanoma-specific survival in worse in the elderly: a multicentric cohort study.. MELANOMA RESEARCH. 2023; 33(6)DOI:10.1097/CMR.0000000000000923. PMID:37696262. IF:1.500(Q3/7D).
01/12/2023
Vitiligo-like hypopigmentation induced by dabrafenib-trametinib: a potential marker for clinical response
Carmona-Rocha, E, Sullivan, I, Yélamos, O. Vitiligo-like hypopigmentation induced by dabrafenib-trametinib: a potential marker for clinical response. MELANOMA RESEARCH. 2023; 33(6)DOI:10.1097/CMR.0000000000000918. PMID:37890183. IF:1.500(Q3/7D).
01/12/2023
High-throughput RNA sequencing of the T cell receptor alpha and beta chains for simultaneous clonality and biological analyses in Sezary syndrome
Blanco, G, López-Aventín, D, Pujol, RM, Gómez-Llonín, A, Puiggros, A, López-Sánchez, M, Estrach, T, García-Muret, MP, López-Lerma, I, Servitje, O, Bellosillo, B, Muro, M, Espinet, B, Rabionet, R, Gallardo, F. High-throughput RNA sequencing of the T cell receptor alpha and beta chains for simultaneous clonality and biological analyses in Sezary syndrome. JOURNAL OF CLINICAL LABORATORY ANALYSIS. 2023; 37(23-24)DOI:10.1002/jcla.24982. PMID:38115685. IF:2.600(Q2/5D).
20/11/2023
Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus
Pereyra-Rodriguez, JJ, Baldrich, ES, Ruiz-Villaverde, R, Torres, EB, Dobao, PD, Nart, IF, Menéndez, AF, Martin-santiago, A, Miquel, JM, Silvestre, JF, Armario-Hita, JC. Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus. ACTA DERMATO-VENEREOLOGICA. 2023; 103DOI:10.2340/actadv.v103.12314. PMID:37982727. IF:3.500(Q1/3D).
14/11/2023
Non-invasive Skin Imaging in Cutaneous Lymphomas
Taleb, E, Yélamos, O, Ardigo, M, Christensen, RE, Geller, S. Non-invasive Skin Imaging in Cutaneous Lymphomas. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2023; 25(1)DOI:10.1007/s40257-023-00824-1. PMID:37964050. IF:8.600(Q1/1D).
06/11/2023
Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials
Yosipovitch, G, Lio, PA, Rosmarin, D, Serra-Baldrich, E, Legat, FJ, Casillas, M, Pierce, E, Liu, ZQ, Sun, LN, Elmaraghy, H, Ständer, S. Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials . BRITISH JOURNAL OF DERMATOLOGY. 2023; 190(2)DOI:10.1093/bjd/ljad435. PMID:37939793. IF:11.000(Q1/1D).
01/11/2023
First update of the living European guideline (EuroGuiDerm) on atopic eczema
Wollenberg A., Kinberger M., Arents B., Aszodi N., Barbarot S., Bieber T., Brough H.A., Pinton P.C., Christen-Zaech S., Deleuran M., Dittmann M., Fosse N., Gáspár K., Gerbens, LAA, Gieler U., Girolomoni G., Gregoriou S., Mortz C.G., Nast A., Nygaard U., Rehbinder E.M., Ring J., Rossi M., Roxburgh C., Serra-Baldrich E., Simon D., Szalai Z.Z., Szepietowski J.C., Torrelo A., Werfel T., Flohr C.. First update of the living European guideline (EuroGuiDerm) on atopic eczema. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(11)DOI:10.1111/jdv.19269. PMID:37328919. IF:8.500(Q1/1D).
01/11/2023
The Influence of the Exposome in the Cutaneous Squamous Cell Carcinoma, a Multicenter Case-Control Study
Navarro-Bielsa, A, Gracia-Cazaña, T, Almagro, M, de la Fuente-meira, S, Flórez, A, Yélamos, O, Montero-Vilchez, T, González-Cruz, C, Diago, A, Abadías-Granado, I, Fuentelsaz, V, Colmenero, M, Bañuls, J, Arias-Santiago, S, Buendía-Eisman, A, Almenara-Blasco, M, Gil-Pallares, P, Gilaberte, Y. The Influence of the Exposome in the Cutaneous Squamous Cell Carcinoma, a Multicenter Case-Control Study. Cancers. 2023; 15(22)DOI:10.3390/cancers15225376. PMID:38001636. IF:4.500(Q1/3D).